Tag: equity
-
Antibody Developer Secures $40M from Foundation Investors
16 May 2014. Kymab Ltd., a developer of human antibodies from mouse genomes, raised $40 million in its second round of venture investment from the Wellcome Trust, an original backer of the company, and Bill & Melinda Gates Foundation. Kymab, based in Cambridge, U.K., is also collaborating with the Gates Foundation in research on discovery…
-
Neurodegenerative Therapies Start-Up Gains $4.8M Seed Funds
12 May 2014. Lysosomal Therapeutics Inc., a start-up developer of therapies for neurodegenerative disorders in Cambridge, Massachusetts, raised $4.8 million in seed financing, the enterprise’s initial operating funds. The company was begun by and is based on the research of Dimitri Krainc, a neurologist at Harvard Medical School and Massachusetts General Hospital in Boston. Atlas…
-
Biotech Alliance to Humanize Pig Lungs for Transplant
7 May 2014. Synthetic Genomics Inc. in La Jolla, California and Lung Biotechnology Inc. in Silver Spring, Maryland are developing synthetic lungs from pigs for patients with end-stage lung diseases needing a transplant. While all financial aspects of the deal were not disclosed, United Therapeutics Corporation — the parent company of Lung Biotechnology — is…
-
Immune Therapeutics Start-Up Raises $37.5M in Early Funding
6 May 2014. Anokion SA in Lausanne, Switzerland, a start-up enterprise developing therapies to treat immune systems disorders, raised 33 million Swiss francs ($US 37.5 million) in its first venture financing round. The round was led by Novartis Venture Fund, and two life-science investment companies — Novo Ventures and Versant Ventures — with participation from…
-
Cisco Venture Arm Backing Internet-of-Things Start-Ups
1 May 2014. Cisco Investments, the venture capital division of the network technologies company, is taking minority stakes in start-up companies and an accelerator that add Internet connectivity to everyday devices and products, known as Internet-of-Things. The company also plans to make $150 million in early-stage investments over the next two to three years on…
-
Cancer Immunotherapy Start-Up Completes $176M Funding Round
25 April 2014. Juno Therapeutics, a biotechnology start-up company in Seattle, completed its first round of venture financing, raising $176 million from private investors and not-for-profit research institutes. The company started in December 2013 with a stake of $120 million, but announced in January 2014 it planned to expand its financing beyond an original target…
-
Genome Editing Start-Up Secures $25 Million in First Round
24 April 2014. Biopharmaceutical start-up company CRISPR Therapeutics in Basel, Switzerland raised $25 million in its first funding round. The company develops engineered gene therapies with a technology developed by one of its scientific founders, and is backed in this round by Versant Ventures, a venture capital company in Menlo Park, California. CRISPR Therapeutics’ technology…
-
Health Care Accelerator Raises $7M for New Initiatives
17 April 2014. Healthbox Global Partners LLC, a Chicago-based business accelerator in the health care industry, says it raised $7 million to fund its operations in six cities in the U.S. as well as support new business models for encouraging innovation. Healthbox is a joint venture of Intermountain Healthcare, a health delivery system in Utah;…
-
Cancer Radiotherapy Company Lands $11.6M First Round Funds
4 April 2014. RefleXion Medical, a company in Burlingame, California designing a more accurate form of radiation therapy to treat solid tumors, gained $11.6 million in its first round of venture financing. The financing was lead by venture capital company Sofinnova Partners, with participation by Pfizer Venture Investments and Venrock. RefleXion Medical is developing a…
-
Baxter Acquiring Hemophilia Gene-Therapy Biotech Company
3 April 2014. Baxter International, a pharmaceutical and medical products company in Deerfield, Illinois is buying Chatham Therapeutics LLC, a developer of gene therapy to treat hemophilia. Under the agreement, Baxter will acquire outstanding LLC interests in Chatham for $70 million, but future milestone payments are also possible. The acquisition gives Baxter access to all…